275.26
price up icon1.97%   5.33
after-market Handel nachbörslich: 275.26
loading
Schlusskurs vom Vortag:
$269.93
Offen:
$268.05
24-Stunden-Volumen:
328.05K
Relative Volume:
0.93
Marktkapitalisierung:
$6.11B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-10.96
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
+2.88%
1M Leistung:
-19.23%
6M Leistung:
-16.13%
1J Leistung:
+22.07%
1-Tages-Spanne:
Value
$265.20
$279.15
1-Wochen-Bereich:
Value
$265.00
$279.15
52-Wochen-Spanne:
Value
$200.63
$377.46

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
Firmenname
Madrigal Pharmaceuticals Inc
Name
Telefon
404-380-9263
Name
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
Mitarbeiter
528
Name
Twitter
@MadrigalPharma
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
MDGL's Discussions on Twitter

Vergleichen Sie MDGL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MDGL
Madrigal Pharmaceuticals Inc
275.26 5.94B 0 -518.67M -438.32M -25.12
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-28 Hochstufung B. Riley Securities Neutral → Buy
2025-02-27 Bestätigt H.C. Wainwright Buy
2024-06-28 Eingeleitet Cantor Fitzgerald Neutral
2024-06-11 Eingeleitet Wolfe Research Outperform
2024-04-22 Eingeleitet BofA Securities Underperform
2024-03-15 Hochstufung B. Riley Securities Sell → Neutral
2024-03-06 Eingeleitet Citigroup Buy
2024-02-26 Herabstufung B. Riley Securities Neutral → Sell
2022-12-20 Bestätigt Oppenheimer Outperform
2022-12-19 Bestätigt H.C. Wainwright Buy
2022-12-19 Bestätigt Piper Sandler Overweight
2022-12-19 Hochstufung Raymond James Underperform → Mkt Perform
2022-07-08 Herabstufung B. Riley Securities Buy → Neutral
2021-10-07 Eingeleitet Jefferies Buy
2021-08-06 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-05-20 Fortgesetzt Goldman Buy
2020-11-24 Fortgesetzt Evercore ISI Outperform
2020-11-06 Bestätigt H.C. Wainwright Buy
2020-07-31 Eingeleitet Piper Sandler Overweight
2020-06-05 Eingeleitet BMO Capital Markets Market Perform
2020-05-05 Eingeleitet Chardan Capital Markets Buy
2020-01-30 Eingeleitet Canaccord Genuity Buy
2020-01-09 Hochstufung UBS Neutral → Buy
2019-11-07 Bestätigt H.C. Wainwright Buy
2019-06-25 Eingeleitet Stifel Hold
2019-06-10 Hochstufung B. Riley FBR Neutral → Buy
2019-02-28 Bestätigt H.C. Wainwright Buy
2019-02-22 Eingeleitet SVB Leerink Outperform
2019-01-23 Eingeleitet UBS Neutral
2018-12-14 Eingeleitet Wolfe Research Outperform
2018-12-12 Eingeleitet B. Riley FBR Neutral
2018-11-19 Herabstufung Raymond James Mkt Perform → Underperform
2018-11-16 Hochstufung Evercore ISI In-line → Outperform
2018-09-04 Eingeleitet Citigroup Buy
2018-08-06 Herabstufung Goldman Buy → Neutral
2018-06-28 Eingeleitet Raymond James Mkt Perform
Alle ansehen

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

pulisher
May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com

May 26, 2025
pulisher
May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK

May 26, 2025
pulisher
May 23, 2025

When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com

May 23, 2025
pulisher
May 17, 2025

In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha

May 17, 2025
pulisher
May 13, 2025

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years - AOL.com

May 13, 2025
pulisher
May 13, 2025

Transcript : Madrigal Pharmaceuticals, Inc.Special Call - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Where are the Opportunities in (MDGL) - news.stocktradersdaily.com

May 13, 2025
pulisher
May 13, 2025

Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN

May 13, 2025
pulisher
May 11, 2025

Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN

May 11, 2025
pulisher
May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus

May 11, 2025
pulisher
May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus

May 11, 2025
pulisher
May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times

May 10, 2025
pulisher
May 10, 2025

Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com

May 10, 2025
pulisher
May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.

May 10, 2025
pulisher
May 08, 2025

Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey

May 08, 2025
pulisher
May 07, 2025

Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey

May 07, 2025
pulisher
May 06, 2025

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra (NASDAQ:MDGL) - Seeking Alpha

May 06, 2025
pulisher
May 06, 2025

Billionaire John Paulson’s 10 Stocks with Huge Upside Potential - Insider Monkey

May 06, 2025
pulisher
May 04, 2025

Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st

May 04, 2025
pulisher
May 03, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025
pulisher
May 03, 2025

Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus

May 03, 2025
pulisher
May 02, 2025

(MDGL) Trading Signals - news.stocktradersdaily.com

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Stron - GuruFocus

May 02, 2025
pulisher
May 02, 2025

UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus

May 02, 2025
pulisher
May 02, 2025

UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN

May 02, 2025
pulisher
May 02, 2025

UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives Increased Price Target from Analyst | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks

May 02, 2025
pulisher
May 01, 2025

Madrigal: Q1 Earnings Snapshot - Huron Daily Tribune

May 01, 2025
pulisher
May 01, 2025

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Zacks Investment Research

May 01, 2025
pulisher
May 01, 2025

Madrigal Pharmaceuticals Q1 Loss Narrows - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: Madrigal Pharmaceuticals beats Q1 2025 EPS forecasts - Investing.com

May 01, 2025
pulisher
May 01, 2025

Madrigal Pharmaceuticals Inc Q1 2025 Earnings: Revenue Surpasses - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Madrigal Pharmaceuticals (MDGL) Reports Strong Q1 Revenue Exceed - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Madrigal’s MASH drug sales again top Wall Street projections - Yahoo Finance

May 01, 2025
pulisher
Apr 29, 2025

Madrigal stock holds neutral as 1Q revenue beats estimates By Investing.com - Investing.com Canada

Apr 29, 2025
pulisher
Apr 29, 2025

Madrigal Pharmaceuticals (MDGL) to Present Key Findings at EASL - GuruFocus

Apr 29, 2025

Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):